UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Apple Turns 50: From Garage Startup to AI Crossroads 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
SAN DIEGO, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be presenting a company overview at the Biotech Showcase 2016 conference on Monday, January 11, 2016 at 3:00 p.m. PT (6:00 p.m. ET) in San Francisco.
A live webcast of the presentation will be available through the investor relations section of the Company's website at www.fatetherapeutics.com. Following the live webcast, an archived replay will be available on the Company's website for 30 days after the conference.
About Fate Therapeutics, Inc.
Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company’s cell-based product pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company’s novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact: Jesse Baumgartner, Stern Investor Relations, Inc. 212.362.1200, [email protected]
